US FDA's action on unapproved nitroglycerin tablets hits Glenmark and Konec
This article was originally published in Scrip
The US FDA has ordered Glenmark Generics of Mahwah, New Jersey, and Konec of Tuscan, Arizona, to stop marketing unapproved nitroglycerin tablets in 0.3mg, 0.4mg and 0.6mg dosages. The action is not a recall, as each product had previously been classified as a grandfathered drug in the US. The agency has taken the action against the products as part of its previously announced "Unapproved Drugs Initiative".
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.